HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.8900
-0.0100 (-0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9000
Open2.0000
Bid1.7000 x 1800
Ask0.0000 x 800
Day's Range1.7050 - 2.0000
52 Week Range1.6900 - 14.9600
Volume89,596
Avg. Volume177,285
Market Cap4.19M
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the second quarter, which ended June 30, 2019, and provides a business update.

  • GlobeNewswire

    Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

    Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovarian cancer in its Phase 1 trial using Ampligen with Intron A and celecoxib. The research team, led by Drs. Robert Edwards, Anda Vlad and Brian Orr, found that Ampligen was well tolerated on an intraperitoneal basis and as a combination therapy. “This concludes that these drugs can be given in this combination with no major toxicities noted and no evidence of added toxicity when adding the immunomodulators to cisplatin as most of the grade 3 toxicities listed above are common with cisplatin,” wrote Dr. Orr in the Phase 1 report.

  • GlobeNewswire

    Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing

    Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI algorithms following the filing of an 8-K on July 22, 2019. The two stock news organizations, Sagient Research and StreetAccount, both misreported that the company was raising $70 million in an Equity Distribution Agreement when, actually, the company was simply renewing a prior EDA that was related to an ATM and making the requisite SEC filings to raise up to $4.5 million under the new EDA, the maximum permitted at this time.

  • ACCESSWIRE

    Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / July 2, 2019 / StockNewsNow.com , The Official MicroCap News Source ™ , today published an SNNLive Video Interview with Thomas Equels, CEO of Hemispherx Biopharma, Inc. (NYSE ...

  • GlobeNewswire

    Hemispherx Biopharma CFO Adam Pascale Announces Retirement

    Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. Pascale joined Hemispherx in 1995 as an accounting manager, rising to the position of Chief Accounting Officer before being named CFO in 2016. Pascale has been an integral part of Hemispherx’s leadership team since being named CFO, helping to execute CEO Thomas K. Equels’ long-term business plan to test the company’s lead product Ampligen in the treatment of cancer.

  • GlobeNewswire

    Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

    Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapies, such as checkpoint blockade therapies. The company has five ongoing immuno-oncology clinical trials, four planned clinical trials and an active Early Access Program (EAP). The most recent addition to the ongoing group is a clinical study in the treatment of prostate cancer, where FDA authorization has been received.

  • GlobeNewswire

    Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

    OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See: https://clinicaltrials.gov/ct2/show/NCT03734692). On receipt of information from clinical sites, it is Hemispherx’ policy to provide periodic updates when a clinical study (1) is FDA authorized, (2) begins enrollment, (3) treats its first subject, (4) issues material interim reports and (5) releases final results. The company is pleased to announce this step in our clinical program, which constitutes steady progress toward Hemispherx’ clinical goals.

  • GlobeNewswire

    Hemispherx Biopharma Stockholders Approve Reverse Stock Split

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders voted in favor to grant the Board of Directors the authority to effect a reverse stock split of the company’s issued and outstanding shares of Common Stock. The proposal passed by approximately 55% of all issued and outstanding shares and approximately 86% of the shares actually voted were voted in favor of the reverse split. Following the stockholder vote, the Board met and approved a 1-for-44 reverse stock split to achieve a value of approximately $5 per share.

  • GlobeNewswire

    Hemispherx Reports 2019 First Quarter Financial Results

    OCALA Fla., May 16, 2019 -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple.

  • GlobeNewswire

    Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

    ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

  • GlobeNewswire

    Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

    Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

  • GlobeNewswire

    Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

    OCALA, Fla., May 08, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet.

  • GlobeNewswire

    Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

    Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — and whose product portfolio includes Ampligen, commercially approved in Argentina, as the world’s only approved therapeutic for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — announced today that the impressive results from a blood-based, real-time diagnostic test out of Stanford University demonstrates an ability to identify moderate to severe ME/CFS patients from normal controls. While Hemispherx is currently focused on Ampligen in the treatment of cancer, for which there are multiple ongoing trials, regulatory approval of Ampligen in the treatment of ME/CFS in the United States is also a corporate goal.

  • ACCESSWIRE

    Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...

  • GlobeNewswire

    Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

    OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) under the leadership of the principal investigator, Robert Edwards, MD. The ovarian cancer program is being funded in part by an Ovarian Cancer Specialized Program of Research Excellence (SPORE) from the National Institutes of Health (NIH), which is supporting a Phase 1/2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer.

  • GlobeNewswire

    Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019

    Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019, at 8:30 a.m. PT. Equels' presentation will focus on the company’s ongoing clinical trials and programs using its flagship investigational drug Ampligen to treat multiple cancer types. The company recently announced significant progress in its Ampligen pancreatic cancer program and multiple Ampligen plus checkpoint blockade immuno-oncology programs.

  • ACCESSWIRE

    MicroCap Review Magazine Spring 2019 Issue Now Available

    The Digital Issue of the Spring 2019 MicroCap Review Magazine,The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / SNN ...

  • GlobeNewswire

    Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer

    OCALA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the company’s new Chief Accounting Officer. Lintal joined Hemispherx in 2018 as VP of Finance & Control. “Ms. Lintal has done a superb job since arriving at Hemispherx and will make an excellent Chief Accounting Officer,” said CEO Thomas K. Equels.

  • GlobeNewswire

    Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab

    OCALA, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug Ampligen® (rintatolimod), a dsRNA TLR3 agonist, in combination with Merck’s Keytruda® (pembrolizumab), an anti-PD-1 check-point blockade therapy, in the treatment of metastatic triple-negative breast cancer.

  • GlobeNewswire

    Hemispherx Reports 2018 Year-end Financial Results

    OCALA, Fla., April 01, 2019 -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business.

  • GlobeNewswire

    Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs

    Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on unmet medical needs in immunology, announced today the first of a series of planned quarterly press release updates highlighting the progress and achievement of milestones in the Company’s ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapy, such as checkpoint blockade therapies. The Company has recently refocused its efforts to concentrate on the use of Ampligen as an immuno-therapy based on preclinical and early clinical evidence supporting the drug candidate’s potential in the fight against cancer. “We believe steady progress in these combination therapy clinical trials will be an important driver for Hemispherx’s long-term success.

  • GlobeNewswire

    Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that the Company’s previously announced rights offering (the “Rights Offering”) expired on Tuesday, March 5, 2019 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $5.3 million in gross proceeds. The results of the Rights Offering and Hemispherx’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Hemispherx are subject to finalization and verification by Hemispherx and its subscription agent.

  • GlobeNewswire

    Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020

    OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today the extension of its Early Access Program (EAP) at the Erasmus Medical Center in the Netherlands using its drug Ampligen in the treatment of pancreatic cancer. The EAP is approved by the Dutch Health Inspectorate until March 9, 2020 to treat pancreatic cancer patients diagnosed with any stage of the serious disease. Approximately 459,000 people globally with 55,000 in the U.S. are diagnosed each year with pancreatic cancer, and it causes approximately 430,000 deaths worldwide and 44,000 in the U.S. according to the Cancer Research Institute (https://www.cancerresearch.org/immunotherapy/cancer-types/pancreatic-cancer).

  • GlobeNewswire

    Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it has extended the initial rights offering subscription period until 5:00 PM Eastern time on March 5, 2019. If you would like to participate, the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee.

  • GlobeNewswire

    Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that it has adjusted certain pricing information for its previously announced rights offering and all of the members of the Company’s senior management and Board of Directors are planning to participate in the rights offering, each member exercising a portion of his respective rights. The subscription period for the rights offering will still expire at 5:00 PM Eastern time on March 1, 2019, unless extended by the Company. The unit pricing remains $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a stated value of $1,000 (and immediately convertible into Hemispherx’s common stock) and warrants to purchase Hemispherx’s common stock.